 |
|
Milestone biodefense publication by Elsevier journal Vaccine
November 20, 2009Last week during the 'Vaccines for Biothreats and Emerging and Neglected Diseases Symposium' in Galveston TX, USA, the Elsevier journal Vaccine released a supplement dedicated to vaccines for biodefense (http://www.sciencedirect.com/science/journal/0264410X). This publication provides a comprehensive, state-of-the-art overview on vaccines that have been developed against a diverse group of human and veterinary pathogens, including Bacillus anthracis, smallpox, and blue tongue.
Biodefense has traditionally been associated with defense against biological warfare agents with an emphasis on military applications. However, the events of October 2001 involving envelopes containing anthrax spores sent through the US Postal Service radically changed our thinking about biodefense. We now recognize the need for biodefense to protect both civilian and military populations against biothreat agents. As research continues to develop biodefense countermeasures, it is clear that vaccines are a critical component of the portfolio to control biothreats.
In their editorial in the supplement, the US Guest Editors Alan Barrett (University of Texas Medial Branch), Shan Lu (University of Massachusetts), and Greg Poland (Mayo Clinic Vaccine Research Group) state that, "the progress in development of vaccines for biothreat agents has been remarkable due to the combined efforts of academia, biotechnology companies, larger pharma, governments, and regulatory authorities, and it is our hope that this supplement may serve as a milestone for this process and a useful reference for people interested in knowing the current status of biodefense vaccine development".
The supplement was launched at the 3rd in a series of symposia around the theme of, 'The Changing Landscape of Vaccine Development', organized by the Sealy Center for Vaccine Development at the University of Texas Medical Branch in Galveston TX, USA in conjunction with the James W. McLaughlin Fellowship Fund (http://www.utmb.edu/scvd/).
The symposium Co-Chair and Co-Guest Editor of the Vaccine Supplement, Alan Barrett judged the conference a great success and said: "By focusing on the progression of biodefense vaccine development from bench to bedside the symposium very successfully brought together experts from industry, academia and government to discuss the latest developments in discovery, preclinical development, clinical trials and vaccine acceptance".
Elsevier
The supplement was launched at the 3rd in a series of symposia around the theme of, 'The Changing Landscape of Vaccine Development', organized by the Sealy Center for Vaccine Development at the University of Texas Medical Branch in Galveston TX, USA in conjunction with the James W. McLaughlin Fellowship Fund (http://www.utmb.edu/scvd/).
The symposium Co-Chair and Co-Guest Editor of the Vaccine Supplement, Alan Barrett judged the conference a great success and said: "By focusing on the progression of biodefense vaccine development from bench to bedside the symposium very successfully brought together experts from industry, academia and government to discuss the latest developments in discovery, preclinical development, clinical trials and vaccine acceptance".
Elsevier
Biodefense Current Events and Biodefense News RSSIowa State University researcher discovers Ebola's deadly secret
Research at Iowa State University has led scientists to uncover how the deadly Zaire Ebola virus decoys cells and eventually kills them.
TGen seeks emergency FDA approval of new swine flu test
The Phoenix-based non-profit Translational Genomics Research Institute (TGen) announced today that, along with a business collaborator, it will submit a request to the U.S. Food and Drug Administration for emergency use of a new test to diagnose the 2009 H1N1 swine flu virus.
Most would refuse emergency use H1N1 vaccine or additive
A majority of Americans would not take an H1N1 flu vaccine or drug additive authorized for emergency use by the Food and Drug Administration, according to a University of Pittsburgh Graduate School of Public Health and University of Georgia study.
New accurate diagnostic test for swine H1N1 influenza using RT-PCR technology
A new, easy-to-perform method for detecting both seasonal influenza A virus and the emerging H1N1 swine-derived influenza A virus in human clinical samples offers a fast, sensitive, and cost-effective diagnostic test that runs on standard laboratory equipment.
Computer simulation captures immune response to flu
Researchers have successfully tested first the first time a computer simulation of major portions of the body's immune reaction to influenza type A, with implications for treatment design and preparation ahead of future pandemics, according to work accepted for publication, and posted online, by the Journal of Virology.
Scientists develop mathematical model to predict the immune response to influenza
Researchers at the University of Rochester have developed a mathematical model to predict immune responses to infection with influenza A viruses, including novel viruses such as the emergent 2009 influenza A (H1N1).
La Jolla Institute announces 2.0 launch of major database to aid vaccine development worldwide
Key improvements in a major infectious disease database that will aid vaccine development worldwide were unveiled today with the 2.0 launch of the National Institutes of Health-sponsored Immune Epitope Database and Analysis Resource (IEDB).
OHSU scientists partner with others to form center aimed at combating infectious diseases
Oregon Health & Science University and the University of Washington, along with a number of partner institutions across the Northwest, have received federal funding to form a regional research center aimed at combating emerging or re-emerging infectious diseases that pose a serious threat to human health.
Revisiting the anthrax attacks
When anthrax was sent through the U.S. Postal Service in 2001, an overwhelming majority of postal workers elected not to be inoculated with the available vaccine because of confusion and distrust, according to a University of Pittsburgh Graduate School of Public Health study.
Nose-spray vaccine against botulism effective in first tests
A preclinical study found a new nasal spray vaccine to provide complete protection against a major botulism toxin, according to a study published today in the Nature journal Gene Therapy.
More Biodefense Current Events and Biodefense News Articles
 |
Biodefense: Principles and Pathogens by M. S. Bronze (Author) "...This book is an encyclopedic source of valid data that should not be lacking from the book collections of hospitals, general practitioners, and all others with a professional (or national defense) interest in infectious diseases and their complications." FEMS Immunology and Medical Microbiology, June 2005, 45 (2005) 351-352 |
 |
Biodefense Nk+ 60 Caps by Swanson Ultra Recommended by 700 Japanese hospitals, immune- stimulating AHCC is the premier ingredient in BioDefense NK+. AHCC stands for "active hexose correlated compound," an extract obtained from a hybridization of mushrooms used in traditional Japanese healing, cultured in a liquid medium. It provides activated hemicellulose, glycoproteins, amino acids, and oligosaccharides with a unique alpha-1,4 glucan structure. We teamed AHCC with BetaRight beta glucans and a 4:1 shiitake extract for cellular protection and total-body immune support. |
 |
Breeding Bio Insecurity: How U.S. Biodefense Is Exporting Fear, Globalizing Risk, and Making Us All Less Secure by Lynn C. Klotz (Author), Edward J. Sylvester (Author) In the years since the 9/11 attacks—and the subsequent lethal anthrax letters—the United States has spent billions of dollars on measures to defend the population against the threat of biological weapons. But as Lynn C. Klotz and Edward J. Sylvester argue forcefully in Breeding Bio Insecurity, all that money and effort hasn’t made us any safer—in fact, it has made us more vulnerable.
Breeding Bio Insecurity reveals the mistakes made to this point and lays out the necessary steps to set us on the path toward true biosecurity. The fundamental problem with the current approach, according to the authors, is the danger caused by the sheer size and secrecy of our biodefense effort.... |
 |
Biodefense: Research Methodology and Animal Models by James R. Swearengen (Editor) The importance attached to rapidly developing our biodefensive capabilities has recently resulted in a significantly increased funding for biodefense research. Accordingly, researchers will respond with an effort equal to the challenge, producing an impressive body of findings. To ensure that this effort continues in the most efficient manner, Biodefense: Research Methodology and Animal Models presents a thorough historical and current review of biodefense research, encouraging researchers to leverage relevant results, rather than duplicate them. By building on the work of others, scientists will be able to proceed in a way that makes the best use of available resources, while avoiding unnecessary duplication of animal research. Including contributions from recognized... |
 |
Biodefense Immune 120 Caps by Nature's Benefit Healthy immune function supports every organ system in the body. Biodefense is the most versatile and complete immune supporting formula available. |
 |
Vaccines for Biodefense and Emerging and Neglected Diseases by Alan D.T. Barrett (Author), Lawrence R. Stanberry (Author) The last 20 years has seen a rapid increase in infectious diseases, particularly those that are termed "emerging diseases" such as SARS, "neglected diseases" such as malaria and those that are deemed biothreats such as anthrax. It is well-recognized that the most effective modality for preventing infectious diseases is vaccination. This book provides researchers with a better understanding of what is currently known about these diseases, including whether there is a vaccine available or under development. It also informs readers of the key issues in development of a vaccine for each disease. * Provides a comprehensive treatise of the agents that are responsible for emerging and neglected diseases and those that can be used as... |
|
Biodefense: Next Steps: Hearing Before the Subcommittee on Bioterrorism and Public Health Preparedness of the Committee on Health, by United States (Author) | |
|
Biodefense Market Report 2006 - Vaccines, Theraputics, and Diagnostics for Bioterror Agents by Melanie C. Trull (Author), Tracey V. du Laney (Author), Mark D. Dibner (Author) | |
|
Bioability & Bioworld Biodefense and Homeland Security: Opportunities for Life Science Companies 2006 by Mark D. Dibner (Editor) | |
 |
BioDefense: How a Combination of Natural Compounds Effectively Destroys Viruses, Bacteria, Fungi and Can Even Protect or Destroy Bioterrorist Diseases Such as Anthrax by Dr. Arthur A. Fierro (Author) The flu pandemic will kill millions of people. Authorities worry about virus and bacteria mutations. In this pioneering book, Dr. Fierro explains new research showing how the flu, staph, strep, even anthrax and other disease-causing viruses, bacteria and fungi can be destroyed or prevented. Diseases are no match for natural compounds explained in this new book. Defend your body—a BioDefense now exists. |
| © 2010 BrightSurf.com |